Annie R Peng1, Walter Swardfager1,2, Neal L Benowitz3, Jasjit S Ahluwalia4, Caryn Lerman5, Nicole L Nollen6, Rachel F Tyndale1,7. 1. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 2. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada. 3. Department of Medicine, and Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA. 4. Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA. 5. Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 6. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA. 7. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), and Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND AND AIMS: Varenicline effectiveness may be related to the level of adherence, which might be reduced by adverse effects such as nausea. The aim of the study was to test a possible effect of nausea on smoking cessation outcomes mediated by adherence. DESIGN: Mediation path analysis. SETTING: Multiple sites within Canada and the United States. PARTICIPANTS: Treatment-seeking smokers receiving varenicline from two smoking cessation clinical trials: Quit2Live (NCT01836276; n = 449) and Pharmacogenetics of Nicotine Addiction Treatment (PNAT) (NCT01314001; n = 421). MEASUREMENTS: Nausea severity was collected through self-report and adherence was biologically assessed using varenicline concentrations (Quit2Live, plasma sample at week 4; PNAT, saliva sample at week 2). In Quit2Live, the end-points were cotinine-verified abstinence at weeks 4, 12 and 26. In PNAT, the end-points were carbon monoxide-verified abstinence at weeks 2, 12 and 26. FINDINGS: Early nausea was not directly associated with abstinence [odds ratio (OR) ranging from 0.73-1.28; P ≥ 0.26]. However early nausea was indirectly associated with lower cessation rates at multiple timepoints (ORs ranging from 0.92-0.94; 95% CI between 0.83-0.99) in a relationship mediated by reduced varenicline adherence (assessed by plasma varenicline concentrations) in the primary trial (Quit2Live). This relationship between nausea, adherence and cessation was similar in direction but weaker in effect size (ORs ranging from 0.98-0.99; 95% CI between 0.90-1.03) in a secondary trial (PNAT), where adherence was assessed using salivary varenicline concentrations. CONCLUSIONS: These data suggest that early nausea during varenicline treatment may be indirectly associated with lower likelihood of smoking cessation through reducing varenicline adherence. Differences in robustness between the trials may be due to the different biological matrices (plasma vs. saliva) and/or timing used to assess varenicline adherence. The results of the first study suggest that improved management of early nausea during varenicline treatment may positively impact smoking cessation success through increasing varenicline adherence.
BACKGROUND AND AIMS: Varenicline effectiveness may be related to the level of adherence, which might be reduced by adverse effects such as nausea. The aim of the study was to test a possible effect of nausea on smoking cessation outcomes mediated by adherence. DESIGN: Mediation path analysis. SETTING: Multiple sites within Canada and the United States. PARTICIPANTS: Treatment-seeking smokers receiving varenicline from two smoking cessation clinical trials: Quit2Live (NCT01836276; n = 449) and Pharmacogenetics of Nicotine Addiction Treatment (PNAT) (NCT01314001; n = 421). MEASUREMENTS: Nausea severity was collected through self-report and adherence was biologically assessed using varenicline concentrations (Quit2Live, plasma sample at week 4; PNAT, saliva sample at week 2). In Quit2Live, the end-points were cotinine-verified abstinence at weeks 4, 12 and 26. In PNAT, the end-points were carbon monoxide-verified abstinence at weeks 2, 12 and 26. FINDINGS: Early nausea was not directly associated with abstinence [odds ratio (OR) ranging from 0.73-1.28; P ≥ 0.26]. However early nausea was indirectly associated with lower cessation rates at multiple timepoints (ORs ranging from 0.92-0.94; 95% CI between 0.83-0.99) in a relationship mediated by reduced varenicline adherence (assessed by plasma varenicline concentrations) in the primary trial (Quit2Live). This relationship between nausea, adherence and cessation was similar in direction but weaker in effect size (ORs ranging from 0.98-0.99; 95% CI between 0.90-1.03) in a secondary trial (PNAT), where adherence was assessed using salivary varenicline concentrations. CONCLUSIONS: These data suggest that early nausea during varenicline treatment may be indirectly associated with lower likelihood of smoking cessation through reducing varenicline adherence. Differences in robustness between the trials may be due to the different biological matrices (plasma vs. saliva) and/or timing used to assess varenicline adherence. The results of the first study suggest that improved management of early nausea during varenicline treatment may positively impact smoking cessation success through increasing varenicline adherence.
Authors: Serena Tonstad; Philip Tønnesen; Peter Hajek; Kathryn E Williams; Clare B Billing; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Hélène M Faessel; Megan A Gibbs; David J Clark; Kevin Rohrbacher; Marilyn Stolar; Aaron H Burstein Journal: J Clin Pharmacol Date: 2006-12 Impact factor: 3.126
Authors: Jon O Ebbert; Kirk D Wyatt; J Taylor Hays; Eric W Klee; Richard D Hurt Journal: Patient Prefer Adherence Date: 2010-10-05 Impact factor: 2.711
Authors: Raymond Niaura; J Taylor Hays; Douglas E Jorenby; Frank T Leone; John E Pappas; Karen R Reeves; Kathryn E Williams; Clare B Billing Journal: Curr Med Res Opin Date: 2008-05-29 Impact factor: 2.580
Authors: Nicole L Nollen; Lisa Sanderson Cox; Qing Yu; Edward F Ellerbeck; Taneisha S Scheuermann; Neal L Benowitz; Rachel F Tyndale; Matthew S Mayo; Jasjit S Ahluwalia Journal: Contemp Clin Trials Date: 2015-12-05 Impact factor: 2.226
Authors: G E Swan; H S Javitz; L M Jack; J Wessel; M Michel; D A Hinds; R P Stokowksi; J B McClure; S L Catz; J Richards; S M Zbikowski; M Deprey; T McAfee; D V Conti; A W Bergen Journal: Pharmacogenomics J Date: 2011-05-24 Impact factor: 3.550